Premium
VIII. New markers in peripheral T‐cell lymphomas: more entities or more confusion?
Author(s) -
Gaulard Philippe,
Leval Laurence
Publication year - 2013
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2082
Subject(s) - biology , cytotoxic t cell , immune system , immunophenotyping , immunology , t cell , cancer research , antigen , genetics , in vitro
Peripheral T-cell lymphomas (PTCLs) are heterogeneous and uncommon malignancies featuring an aggressive clinical course and a mostly poor outcome with current treatment strategies [1]. Recent developments using genome-wide molecular profiling methods have provided novel insights into their pathobiology and identified new markers with diagnostic, prognostic and/or therapeutic implications.Cell lineageanddifferentiation [markersofgdor natural killer (NK) lineage, cytotoxic immunophenotype, follicular helper T-cell differentiation] account in part for the tumour biology and represent useful features to refine the diagnostic and prognostic stratification of the patients. Novel genetic aberrations are being discovered (ITK-SYK translocation, IRF4/MUM1 andDUSP22 rearrangements, IDH2, TET2, STAT3 and JAK3 point mutations), that may serve as diagnostic genetic markers. Deregulated molecules within oncogenic pathways (NF-kB, Syk, PDGFRa) and immunoreactive cell-surface antigens (CD30, CD52) are being exploited as potential targets for the development of novel therapies.